Tag Archives: Horizon Pharma

December, 2018

May, 2017

December, 2016

  • 9 December

    Horizon Pharma’s Actimmune Fails in Late-Stage Study in Friedreich’s Ataxia

    DUBLIN, Ireland, Dec. 08, 2016 (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the Phase 3 trial, STEADFAST (Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich’s Ataxia study), evaluating ACTIMMUNE® …

September, 2016

July, 2015

  • 8 July

    Horizon Pharma Offers to Acquire Depomed in a $3 Billion Deal

    DUBLIN, IRELAND — (Marketwired) — 07/07/15 — Horizon Pharma plc (NASDAQ: HZNP) Transaction would generate significant revenue and operating synergies, tax savings and would also be immediately and substantially accretive to Horizon’s adjusted diluted earnings per share Projected full-year pro forma combined 2015 net sales and adjusted EBITDA would be …